Abstract: NOTCH1 is frequently mutated in adenoid cystic carcinoma (ACC). To test the idea that immunohistochemical (IHC) staining can identify ACCs with NOTCH1 mutations, we performed IHC for activated NOTCH1 (NICD1) in 197 cases diagnosed as ACC from 173 patients. NICD1 staining was positive in 194 cases (98%) in 2 major patterns: subset positivity, which correlated with tubular/cribriform histology; and diffuse positivity, which correlated with a solid histology. To determine the relationship between NICD1 staining and NOTCH1 mutational status, targeted exome sequencing data were obtained on 14 diffusely NICD1-positive ACC specimens from 11 patients and 15 subset NICD1-positive ACC specimens from 15 patients. This revealed NOTCH1 gain-of-function mutations in 11 of 14 diffusely NICD1-positive ACC specimens, whereas all subsetpositive tumors had wild-type NOTCH1 alleles. Notably, tumors with diffuse NICD1 positivity were associated with significantly worse outcomes (P = 0.003). To determine whether NOTCH1 activation is unique among tumors included in the differential diagnosis with ACC, we performed NICD1 IHC on a cohort of diverse salivary gland and head and neck tumors. High fractions of each of these tumor types were positive for NICD1 in a subset of cells, particularly in basaloid squamous cell carcinomas; however, sequencing of basaloid squamous cell carcinomas failed to identify NOTCH1 mutations. These findings indicate that diffuse NICD1 positivity in ACC correlates with solid growth pattern, the presence of NOTCH1 gain-of-function mutations, and unfavorable outcome, and suggest that staining for NICD1 can be helpful in distinguishing ACC with solid growth patterns from other salivary gland and head and neck tumors.
A denoid cystic carcinoma (ACC) is an uncommon cancer that usually arises in the salivary glands or other secretory glands of the head and neck, upper airways, and breast (for recent review, see Dillon et al 1 ) . Although most cases are slow growing, ACC has a propensity for local spread due to perineural invasion and often ultimately metastasizes, most commonly to the lung, bone, and liver. Local or distal recurrence after surgical resection, with or without radiation therapy, is common, and for these patients the prognosis is poor, even with aggressive chemotherapy regimens.
ACC has several growth patterns, including tubular, cribriform, and solid. Tumors with tubular/cribriform growth patterns are composed of mixtures of p63-positive myoepithelial cells and KIT-positive epithelial cells, which form luminal or gland-like structures. By contrast, tumors with solid growth patterns are comprised mainly of KITpositive epithelial cells and have been associated with worse outcomes. [2] [3] [4] [5] Many ACCs show a mixture of growth patterns, and some studies suggest that even a minor tumor component showing a solid growth pattern imparts a less favorable prognosis. 5 Notch receptors participate in a conserved signaling pathway that regulates many cell fate decisions and has diverse cell lineage-dependent effects on cellular behavior (for recent review, see Bray 6 ). Notch signaling depends of successive ligand-induced cleavages. The first is carried out by ADAM metalloproteases, which cleave at a site within the juxtamembrane negative regulatory region of Notch. This sets the stage for a second cleavage carried out by gamma-secretase, which allows the intracellular portion of Notch to translocate to the nucleus and turn on Notch target genes. Genes encoding Notch receptors and other components of the Notch pathway are recurrently mutated in many cancers, including ACC. [7] [8] [9] [10] [11] We recently noted in a small series of primary ACCs and patientderived xenograft models that epithelial differentiation in ACC is associated with activation of NOTCH1, [12] [13] [14] as assessed by immunohistochemical (IHC) staining with a rabbit monoclonal antibody specific for a neoepitope located at the N-terminus of the NOTCH1 intracellular domain (NICD1) that is created when NOTCH1 is activated by gamma-secretase cleavage. 15 These findings suggested that IHC staining for NICD1 might provide a simple, rapid, and inexpensive means of identifying NOTCH1-mutated ACCs with solid growth patterns, a subtype that can be diagnostically challenging, particularly in small biopsies with limited tumor sampling.
In this study, we tested these ideas by performing NICD1 IHC on a large cohort of ACC specimens as well as a panel of epithelial salivary gland and head and neck tumors. We find that NICD1 staining is a common feature among the diverse tumors studied, but that diffuse NICD1 positivity, which correlates with the presence of NOTCH1 gain-of-function mutations, is restricted to ACCs with solid growth patterns. Notably, we also find that ACCs with diffuse NICD1 positivity in our cohort are associated with a worse outcome. These studies suggest that IHC for NICD1 is useful in identifying ACCs with pathogenic mutations in NOTCH1 and has value as a prognostic marker.
MATERIALS AND METHODS

Cases
Formalin-fixed paraffin-embedded (FFPE) samples were obtained from the tissue archives of Massachusetts General Hospital and Brigham and Women's Hospital with Institutional Review Board approval. FFPE samples were cut at 4 μm thickness, transferred to Superfrost Plus charged slides, and baked for 60 minutes at 60°C before IHC. Tumors were characterized for growth pattern as tubular/cribriform, solid, mixed tubular/cribriform, and solid, or too scant to reliably assess growth pattern. Case characteristics are summarized in Table 1 .
Immunohistochemistry
To explore the association between NOTCH1 activation and histologic features in ACC, we performed immunohistochemistry on 197 FFPE cases diagnosed as ACC from 173 patients. 15 IHC was carried out on a Leica Bond III automated immunostainer following Bond Epitope Retrieval 2 for 40 minutes. NICD1 staining was performed using rabbit monoclonal antibody clone D3B8 (Cell Signaling Technologies, Beverly, MA) at 1:50 for 60 minutes. Staining with diaminobenzidine was developed using the Bond Polymer Refine Detection Kit (Leica). Slides were counterstained with hematoxylin. Scoring of IHC results (negative, subset positive, or diffusely positive) was done independently by J.C.A. and by W.C.F. and D.P.S. Diffuse positivity was defined as staining in > 90% of cells within a high power (40×) field in an immunoreactive area of the tumor (judged by positive NICD1 staining in endothelial cells, which constitute an internal positive control 15 ). Subset positivity was defined as staining in <90% of cells within a high power (40×) field within immunoreactive areas of the tumor, while negative was defined as the absence of staining in tumor cells within immunoreactive areas of the tumor.
Next-generation Targeted Exome Sequencing
Next-generation sequencing was performed on all ACCs with diffuse NICD1 staining for which adequate viable FFPE samples were available (n = 15), as well as 15 ACCs with subset NICD1 staining, which were selected at random based on tissue availability. Targeted exome sequencing was performed using an NGS assay (OncoPanel) that detects somatic mutations, copy number variations, and structural variants in tumor DNA extracted from FFPE samples. 16, 17 The assay covers the exonic sequences of 300 cancer genes and also surveys 113 introns across 35 genes for genomic rearrangements. Areas of tumor in unstained slides were manually removed with a razor blade and used for DNA isolation. DNA (200 ng) was enriched for sequences of interest using a solution phase Agilent SureSelect hybrid capture kit and then used for library preparation. Libraries were sequenced on an Illumina HiSeq 2500 sequencer. Sequence reads were aligned to human reference genome GRCh37 (hg19) with the Burrows-Wheeler Alignment tool. 18 Aligned data were sorted, duplicate marked, and indexed with Picard tools. Base-quality score recalibration and local realignment around insertions and deletions was achieved with the Genome Analysis Toolkit. 19, 20 Single nucleotide (20) variants were called with MuTect. 21 Copy number alterations were determined by comparing normalized sample depth of coverage against a median from a panel of normal samples using an internally developed algorithm (RobustCNV). Structural variants were detected from aligned sequence data using BreaKmer. 17 
Nanostring Analysis
To detect truncated NOTCH1 mRNA transcripts in ACC biopsies, an antisense probe set was designed and synthesized by Nanostring that included probes specific for individual exons or spliced exon pairs spanning exons 2 to 34 of NOTCH1. RNA was isolated from paraffin sections containing ACC using an RNeasy FFPE kit (Qiagen). RNA quantified on a NanoDrop spectrophotometer was hybridized to probe sets, captured on an nCounter cartridge, and quantified on a Nanostring Digital Analyzer. nSolver software was used to normalize the data, which was then exported to Excel for further analysis.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed according to established methods using a laboratory developed, break-apart probe set for detection of MYB rearrangement. Bacterial artificial chromosomes for probe construction were selected using the University of California Santa Cruz Biotechnology Genome Browser and Database (http://genome.ucsc.edu, genome assembly hg38) and obtained from Invitrogen (Carlsbad, CA). DNA was isolated from bacterial cultures using the Plasmid Maxi Kit (Qiagen, Valencia, CA) and fluorescently labeled via nick translation (Abbott Molecular, Des Plaines, IL). Clone specificity was verified by polymerase chain reaction and by FISH to metaphase chromosome spreads prepared from normal male blood specimens.
Survival Analysis
Patient information was obtained from the electronic medical record of Partners Healthcare under a protocol approved by the Institutional Review Board. Patient vitality was determined from the electronic medical record and from publicly available information (eg, obituaries). Kaplan-Meier curves were generated with GraphPad Prism 7 software. The significance of differences in survival between groups was assessed using the Log-rank (Mantel-Cox) test.
RESULTS
Relationship Between Growth Pattern and NOTCH1 Activation in ACC
Virtually all tumors diagnosed as ACC, regardless of growth pattern, stained positively for NICD1 (Table 2) ; representative images of NICD1 staining are shown in Figure 1 . All but 2 tumors with a tubular/cribriform growth pattern were positive for NICD1 in at least a subset of cells, often in a suprabasilar pattern (Fig. 1A) , consistent with prior work showing that p63-positive myoepithelial cells are NICD1 negative. 14 By contrast, 13 of 16 ACCs with a solid growth pattern were diffusely positive for NICD1 (81%) (Fig. 1B) , whereas tumors with mixed tubular/cribriform and solid growth patterns showed a mixture of NICD1 staining patterns (Table 2) , with diffuse NICD1 positivity typically correlating with areas with a solid growth pattern. We also noted, in the process of staining ACCs of salivary gland origin, that normal salivary gland epithelium was uniformly negative for NICD1 (Fig. 1A ). Three tumors diagnosed as ACC were completely negative for NICD1 staining. One was a tumor with classic tubular/cribriform ACC morphology. A second NICD1-negative tumor arose in the middle turbinate and exhibited an unusual ribbon-like growth pattern (Fig. 1C) . The third NICD1-negative tumor was a lung metastasis from a sinonasal mass that showed basaloid features, nuclear pleomorphism, and focal gland-like microcystic structures (Fig. 1D ). Positive staining was observed in internal positive control cells (endothelial cells and/or adjacent benign squamous mucosa) in all 3 of these cases, suggesting that each of these tumors is a true negative.
Diffuse NICD1 Staining Correlates With NOTCH1 Mutation Status in ACC
We hypothesized that ACCs with diffuse NICD1 positivity would be enriched for cases with NOTCH1 gain-of-function mutations. To test this idea, targeted exome sequencing was performed successfully on DNA isolated from 29 FFPE specimens: 14 with diffuse NICD1 positivity and either solid (n = 13) or tubular/cribriform (n = 1) growth patterns; and 15 with subset NICD1 positivity and either tubular/cribriform growth patterns (n = 14) or tubular/cribriform and focally solid growth patterns (n = 1) ( Table 3) . Diffuse NICD1 positive cases selected for study included 3 different biopsies from 1 patient and 2 different biopsies from a second patient. Of the 14 tumors with diffuse NICD1 positivity, we found that 11 harbored sequence variants within NOTCH1 mutational hotspots (exons 25 to 28, exon 34) that are predicted to produce NOTCH1 gain of function. The observed frequency of NOTCH1 mutations in ACCs from different patients that are diffusely positive for NICD1 (8/11 tumors, or 73%) is substantially higher than the frequency of NOTCH1 mutations that has been observed in NGS studies on unselected ACCs. [7] [8] [9] [10] [11] By contrast, none of the 15 tumors with subset positivity for NICD1 had NOTCH1 mutations, a frequency significantly lower than that observed in ACCs with diffuse NICD1 positivity (P < 0.001, Fisher exact test). Different NOTCH1 mutations (n = 11) in this ACC cohort include a range of examples of the 2 major types of gain-of-function mutations previously identified in human cancers: mutations in exons 25 to 28 that lead to ligand-independent NOTCH1 activation 22 ; and mutations in exon 34 that result in deletion of the C-terminal NOTCH1 PEST domain. Identified mutations in exons 25 to 28 include 2 mutations in the Lin12-Notch repeats and several point substitutions/deletions in the core of the Notch negative regulatory region ( Fig. 2A) , as well as 2 in-frame insertions stemming from small duplications (Fig. 2B ). In addition, 3 different tumor biopsies from another patient showed loss of NOTCH1 exons 1 to 27 in one allele. This pattern of copy number loss is consistent with the presence of a rearranged, truncated NOTCH1 allele expressing short NOTCH1 transcripts containing only exons 28 to 34, a type of activating mutation described previously in triple negative breast cancer. 13, 24 To evaluate this possibility, we performed Nanostring analysis of tumor RNA using a probe set spanning the NOTCH1 locus (Fig. 2C ). This revealed excess signal for NOTCH1 exons 28 to 34 relative to exons 1 to 27 in all 3 tumor samples with a 5′ NOTCH1 copy number loss (P < 0.0001, 2-sided t test) as well as in a control triple negative breast cancer cell line, MB-157, that contains only truncated NOTCH1 alleles. 13 By contrast, samples from ACCs without NOTCH1 genomic copy number variation lacked NOTCH1 RNA 5′/3′ exon imbalances. FIGURE 2. NOTCH1 mutations in ACC. A, Positions of point substitutions and in-frame indels in the NOTCH1 extracellular negative regulatory region. NOTCH1 structure is modeled based on x-ray crystallographic studies of Gordon et al. 23 B, Sequence of juxtamembrane insertional mutations caused by small NOTCH1 duplications in biopsies of ACC involving the trachea and liver in the same ACC patient. Residues in red correspond to duplicated amino acid residues; residues in green correspond to unique intervening amino acid residues; and residues in black correspond to normal, unduplicated amino acid residues. Highlighted AV residues in the sequence from the tracheal biopsy corresponds to the normal site of ADAM cleavage in NOTCH1, while highlighted residues in the sequence from the liver biopsy corresponds to the NOTCH1 transmembrane domain. C, Nanostring analysis of RNA isolated from FFPE ACC tissue. RNA was isolated from 2 specimens containing ACCs with wild-type NOTCH1 alleles; 4 ACC specimens with NOTCH1 alleles with point substitutions or small indels (NOTCH1 mutated); 3 ACC specimens with loss of copy number spanning NOTCH1 exons 1 to 27; and the triple negative breast cancer cell line MB-157, which has homozygous or hemizygous NOTCH1 rearrangements and lacks NOTCH1 exons 1 to 27. 13 RNA abundance expressed as Nanostring signal strength (y axis) for each exon covered by probes spanning the NOTCH1 locus (x axis) was first normalized using average signal strength internal control housekeeping genes and then was expressed relative to signal strength for a NOTCH1-mutated ACC with no evidence of allelic imbalance, for which signal strength for each exon was arbitrarily set at 1. Note that excess signals for NOTCH1 exons 28 to 34, which encode the NOTCH1 transmembrane domain and intracellular domain, is seen in the control MB-157 triple negative breast cancer cell line (black) and in the 3 samples (red) prepared from specimens with copy number loss involving exons 1 to 27.
Diffusely NICD1 Positive ACC is Associated With MYB Rearrangements
ACC is often associated with rearrangements involving the MYB gene on chromosome 6p that lead to MYB overexpression. 7, 14 To confirm that the subset of ACCs with diffuse NICD1 positivity is associated with MYB gene rearrangements, we performed FISH with "split apart" probes flanking MYB on 9 diffusely NICD1 positive cases, using subset NICD1 positive ACC cases as controls (n = 6). All 9 diffusely NICD1 positive cases produced abnormal hybridization signals (Table 4 ). In 8 of these cases, the signals were consistent with the presence of a MYB rearrangement, while in 1 case 1 of 2 MYB signals were lost. However, NGS on this case revealed that all of MYB's 15 exons were retained on both alleles ( Table 3 ), indicating that this tumor also contains a MYB rearrangement rather than a MYB deletion. Thus, MYB gene rearrangements seem to be common in ACCs with diffuse NICD1 positivity.
Diffuse NICD1 Staining Correlates With Outcome in ACC
To determine whether NICD1 staining pattern correlates with outcome, we obtained vitality data for all patients whose tumors were subjected to IHC and NOTCH1 mutational analysis, including one patient on whose tumor attempted sequencing failed. Kaplan-Meier analysis revealed that ACCs with diffuse NICD1 positivity were associated with significantly worse outcome than NICD1 subset positive tumors (median survival of 56.5 vs. 140 mo, P = 0.003) (Fig. 3) .
NICD1 Staining and Notch Mutations in NonACCs
The differential diagnosis of ACC includes other benign and malignant basaloid epithelial tumors of salivary gland and other regions of the head and neck. Few of these tumors have been subjected to NGS to date, and we, therefore, used NICD1 IHC to screen a diverse group of non-ACCs for tumors that might harbor NOTCH1 gain-of-function mutations. As shown in Table 5 , a high fraction of non-ACCs also showed subset NICD1 positivity. Clear-cut diffuse NICD1 positivity was not observed, but we noted that basaloid squamous cell carcinoma (bSCC) often was strongly NICD1-positive in a subset of cells (Fig. 4) .
To exclude the occurrence of NOTCH1 gain-offunction mutations in bSCC, a tumor that has not been previously characterized by genomic sequencing, NGS was performed on all 13 cases (Table 6 ). This revealed that bSCC is commonly associated with TP53 mutations (8/13 cases) and with genomic instability marked by segmental gains and losses in numerous chromosomes (all cases), features that are less frequently seen in ACC ( Table 3) . As a further point of comparison with ACC, FISH analysis also was performed, which identified frequent changes in copy number involving MYB but only identified 1 tumor with a MYB gene rearrangement (Table 3 ). Three mutations involving Notch genes were identified. One mutation, P2415del, is an in-frame deletion of a proline residue within an unstructured C-terminal NOTCH1 region of unknown functional significance. The other 2 mutations, R1608* and H2107Gfs*4, disrupt regions of NOTCH1 that are required for function and therefore correspond to loss-of-function mutations. Thus, despite frequent evidence of NOTCH1 activation in bSCC, mutational data point to selective pressure for loss of Notch function in this tumor.
DISCUSSION
This study shows that diffuse NICD1 staining is common in ACCs with solid growth patterns, is highly associated with NOTCH1 gain-of-function mutations, and is associated with worse outcomes. Among tumors of salivary gland and head and neck origin, activation of NOTCH1 is a common feature, but only ACCs show diffuse NICD1 positivity and NOTCH1 mutations in a subset of cases, suggesting that the selective pressure for Notch gain-of-function mutations is specific for ACC among this group of tumors. Prior NGS studies of ACC have identified NOTCH1 gain-of-function mutations in a subset of cases, varying from 0% to 19% (overall 12/172 cases, or 7%). [7] [8] [9] [10] By contrast, we detected NOTCH1 mutations in 8 of 11 ACCs (73%) with diffuse NICD1 positivity, suggesting that NICD1 staining is effective at identifying ACCs with dysregulated NOTCH1 signaling. Our findings add to the weight of evidence implicating Notch signaling in the pathogenesis of ACC and have several translational implications. Among other epithelial cancers, only triple negative breast cancer has been reported to be associated with NOTCH1 gain-of-function mutations. 13, 24 The association of ACCs with a solid growth pattern and diffuse NICD1 positivity suggests that NICD1 staining may be of diagnostic utility in this subset of ACCs, particularly in small biopsies, albeit with an important caveat. In reviewing our ACC cohort, we noted that NICD1 staining intensity often varied from area to area and that patchy negative areas were not uncommon. The NICD1 epitope is in an unstructured region of the intracellular domain of NOTCH1, 25 which may make it susceptible to degradation posttumor resection. This limitation is partially mitigated by the existence of internal positive control cells, such as vascular endothelial cells, in virtually all tissue biopsies. Conversely, lack of NICD1 staining in several of our cases may stem from misdiagnosis. One NICD1-negative neoplasm arising in the middle turbinate had an unusual ribbon-like growth pattern, while a second NICD1-negative tumor, a lung metastasis from a sinonasal mass, had a morphology that was reminiscent of HPV-related carcinoma with adenoid cystic-like features. 26 Further work is needed to determine the value of NICD1 staining in the differential diagnosis of epithelial neoplasms. The association of diffuse NICD1 staining and worse outcome also suggests that NICD1 staining is a useful prognostic marker for ACC, an idea that is reinforced by a recent report showing that NOTCH1 mutations are associated with worse outcome in ACC patients. 27 Finally, clinical trials of several Notch pathway inhibitors are underway in patients with relapsed/ refractory ACC. Prior work has shown that high levels of NICD1 in T-cell acute lymphoblastic leukemia (T-ALL) and triple negative breast cancer cell lines correlate with sensitivity to gamma-secretase inhibitors, 13, 28 and T-ALLs that have shown the greatest response to gamma-secretase inhibitors in the context of clinical trials have been NOTCH1 mutated. 29, 30 Thus, it is possible that diffuse NICD1 positivity may be predictive of tumor response to Notch pathway inhibitors. We acknowledge, however, that while solid growth pattern, NOTCH1 mutation, and diffuse NICD1 staining are associated, these correlations are not uniform in all cases; thus, further work will be necessary to determine which of these markers, alone or in combination, is most informative.
Several of the NOTCH1 mutations we identified in ACC are unusual. Two in-frame insertions due to sequence duplications occurred in a primary tracheal tumor and a liver metastasis from the same patient, suggesting that the genetic background in this tumor predisposed to this rare type of NOTCH1 mutation. A pathogenic mutation also was identified in the mismatch repair gene PMS2 in both specimens, but typical indel mutations indicative of a mismatch repair defect were not seen in the NGS data sets and the basis for recurrent insertional NOTCH1 mutations in this tumor is unclear. We also noted that 3 of 4 PEST domain mutations fell in codon 2466 or 2467, a site that is mutated at low frequency in other tumors, such as T-ALL. 28 Of note, of 9 NOTCH1 exon 34 mutations reported in ACC by other groups, 5 affected codon 2467, 9, 10 suggesting that this is a mutational hotspot in ACC. Enrichment for specific PEST domain mutations is not a prominent feature in T-ALL, but is characteristic of chronic lymphocytic leukemia, in which ∼90% of mutations are a del(CT) involving codon 2514. 31, 32 The same del (CT) mutation also appears to be a mutational hotspot in mantle cell lymphoma. 33 Whether these tumor-specific mutational patterns reflect selective pressure for loss of different C-terminal regions of NOTCH1 in different cell contexts or are a manifestation of differing mutational mechanisms in various tumors remains to be determined.
Our mutational data also sound a note of clinical caution. Three of the identified NOTCH1 gain-of-function mutations, a deletion spanning exons 1 to 27 of NOTCH1 and 2 insertional mutations that reduplicate juxtamembrane sequences, create mutated alleles encoding receptors that are resistant to NOTCH1 inhibitory antibodies 34 that have been tested in clinical trials, including in patients with ACC (NCT02662608); thus, our findings suggest that if inhibitory antibody therapy is to be given, NOTCH1 mutational testing should be carried out to ensure that the tumor is expressing a "targetable" form of NOTCH1. By contrast, because the antibody used to stain NICD1 recognizes a neoepitope created by gamma-secretase cleavage, mutated NOTCH1 receptors in tumors with diffuse NICD1 positivity should be "targetable" by gamma-secretase inhibitors, regardless of the mechanism of NOTCH1 activation. 
